Penserra Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
CI
Penserra Capital Management's RETA Position: Q4 2021 in Review
Penserra Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 720 shares — an estimated $72K sold.
Penserra Capital Management first reported a position in RETA in Q4 2020 and held it in 4 quarters. The position peaked at $101K in Q2 2021. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.
- Penserra Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
- Penserra Capital Management sold 720 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $72K.
- Penserra Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 4 quarters.
- Penserra Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $101K in Q2 2021.
- 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.
Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.